GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of GDC-0575 Alone and in Combination With Gemcitabine in Participants With Refractory Solid Tumors or Lymphoma
- First Posted Date
- 2012-03-27
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT01564251
- Locations
- 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT01562275
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01547546
A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT01546519
A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)
- First Posted Date
- 2012-03-06
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 258
- Registration Number
- NCT01545440
A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)
- First Posted Date
- 2012-03-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 205
- Registration Number
- NCT01545453
A Study of MCAF5352A in Healthy Volunteers
- First Posted Date
- 2012-02-29
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT01540760
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT01522664
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT01519804
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 259
- Registration Number
- NCT01496742
© Copyright 2024. All Rights Reserved by MedPath